{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:43:28Z","timestamp":1792583008814,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01029-4","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:11:36Z","timestamp":1792581096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Real-World Outcomes Among Patients with Major Depressive Disorder with Anxiety-Related Diagnosis Taking Brexpiprazole as Augmentation with Antidepressant Treatment"],"prefix":"10.1007","author":[{"given":"Stevan Geoffrey","family":"Severtson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusica Hadzi","family":"Boskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Marci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra F.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abdrabboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"24","key":"1029_CR1","first-page":"643","volume":"72","author":"B Lee","year":"2023","unstructured":"Lee B, Wang Y, Carlson S, Greenlund K, Lu H, Liu Y, et al. National, state-level, and country-level prevalence estimates of adults aged \u226518 years self-reporting a lifetime diagnosis of depression\u2014United States, 2020. Morbid Mortal Wkly Rep. 2023;72(24):643\u201350.","journal-title":"Morbid Mortal Wkly Rep"},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2147\/NDT.S246294","volume":"16","author":"T Inoue","year":"2020","unstructured":"Inoue T, Kimura T, Inagaki Y, Shirakawa O. Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder. Neuropsychiatr Dis Treat. 2020;16:1695\u2013704.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jad.2018.08.053","volume":"242","author":"JR Vittengl","year":"2019","unstructured":"Vittengl JR, Clark LA, Smits JAJ, Thase ME, Jarrett RB. Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression? J Affect Disord. 2019;242:150\u20138.","journal-title":"J Affect Disord"},{"issue":"7","key":"1029_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"HE Pigott","year":"2023","unstructured":"Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study\u2019s patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7):e063095.","journal-title":"BMJ Open"},{"key":"1029_CR5","doi-asserted-by":"crossref","unstructured":"Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4).","DOI":"10.4088\/JCP.17m12058"},{"key":"1029_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jad.2016.05.013","volume":"201","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116\u201323.","journal-title":"J Affect Disord"},{"issue":"8","key":"1029_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","volume":"65","author":"D Mrazek","year":"1996","unstructured":"Mrazek D, Hornberger J, Altar C, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 1996;65(8):977\u201387.","journal-title":"Psychiatr Serv"},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"A Rush","year":"2006","unstructured":"Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"1029_CR9","doi-asserted-by":"crossref","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2).","DOI":"10.4088\/JCP.20m13699"},{"key":"1029_CR10","unstructured":"Administration USFD. Rexulti\u00ae (brexpiprazole) tablets, for oral use. 2025."},{"issue":"11","key":"1029_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ijnp\/pyz040","volume":"22","author":"T Kishi","year":"2019","unstructured":"Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2019;22(11):698\u2013709.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1029_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/NDT.S185815","volume":"15","author":"ME Thase","year":"2019","unstructured":"Thase ME, Weiller E, Zhang P, Weiss C, McIntyre RS. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2019;15:37\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1029_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JCP.0000000000001034","volume":"39","author":"M Hobart","year":"2019","unstructured":"Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. J Clin Psychopharmacol. 2019;39(3):203\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"1029_CR14","doi-asserted-by":"crossref","unstructured":"Hadzi Boskovic D, Huang D, Severtson S. Clinical outcomes among patients taking brexpiprazole as augmentation with antidepressant treatment for major depressive disorder in a United States real-world dataset. . Neurol Ther. 2026 (submitted for publication).","DOI":"10.1007\/s40120-026-01027-6"},{"issue":"12","key":"1029_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40263-024-01124-w","volume":"38","author":"M Kato","year":"2024","unstructured":"Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. A multicenter, open-label study to evaluate the long-term safety and efficacy of adjunctive brexpiprazole 2 mg daily in Japanese patients with major depressive disorder. CNS Drugs. 2024;38(12):1003\u201316.","journal-title":"CNS Drugs"},{"issue":"7","key":"1029_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/07067437241233965","volume":"69","author":"F Therrien","year":"2024","unstructured":"Therrien F, Ward C, Chokka P, Habert J, Ismail Z, McIntyre RS, et al. Adjunctive brexpiprazole for patient life engagement in major depressive disorder: a Canadian, phase 4, open-label, interventional study: brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble depressif majeur: une etude interventionnelle canadienne ouverte de phase 4. Can J Psychiatry. 2024;69(7):513\u201323.","journal-title":"Can J Psychiatry"},{"key":"1029_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer R, Williams J. The PHQ-9: validation of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1029_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"R Spitzer","year":"2006","unstructured":"Spitzer R, Kroenke K, Williams J, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"key":"1029_CR19","unstructured":"Guy W, National Institute of Mental Health . Psychopharmacology Research B, Early Clinical Drug Evaluation P. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, Md: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jad.2025.01.152","volume":"376","author":"P Alves","year":"2025","unstructured":"Alves P, Marci CD, Cohen-Stavi CJ, Whelan KM, Boussios C. A machine learning model using clinical notes to estimate PHQ-9 symptom severity scores in depressed patients. J Affect Disord. 2025;376:216\u201324.","journal-title":"J Affect Disord"},{"key":"1029_CR21","unstructured":"Leavy M, Bryant Z, Marci CD, Boussios C. Artificial intelligence-based estimation of the CGI-I to address gaps in real-world data and increase study sample size. International Society for Pharmaceutical Engineering Annual Meeting; Washington DC, USA 2025."},{"issue":"1","key":"1029_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12913-021-06729-1","volume":"21","author":"J Jeffrey","year":"2021","unstructured":"Jeffrey J, Klomhaus A, Aralis H, Barrera W, Rosenberg S, Grossman M, et al. Factors associated with response and remission from depression at 6-months of treatment in a retrospective cohort treated within an integrated care program. BMC Health Serv Res. 2021;21(1):703.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"1029_CR23","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum S. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"11","key":"1029_CR24","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.4088\/JCP.14m08992","volume":"75","author":"HA Croft","year":"2014","unstructured":"Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1029_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-8-4","volume":"8","author":"Q Jiang","year":"2009","unstructured":"Jiang Q, Ahmed S. An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Ann Gen Psychiatry. 2009;8:4.","journal-title":"Ann Gen Psychiatry"},{"issue":"39","key":"1029_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008142","volume":"96","author":"G Li","year":"2017","unstructured":"Li G, Shen Y, Luo J, Li H. Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: a pooled analysis of 4 Chinese clinical trials. Medicine (Baltimore). 2017;96(39):e8142.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1029_CR27","doi-asserted-by":"publisher","first-page":"pyaf074.","DOI":"10.1093\/ijnp\/pyaf074","volume":"28","author":"S Kapadia","year":"2025","unstructured":"Kapadia S, Zhang Z, Ardic F, Patel M, Thase ME, Papakostas GI. Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2025;28(10):pyaf074.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1029_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1080\/13696998.2025.2549653","volume":"28","author":"S Awasthi","year":"2025","unstructured":"Awasthi S, Hadzi Boskovic D, Kapadia S. Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder. J Med Econ. 2025;28(1):1348\u201356.","journal-title":"J Med Econ"},{"issue":"2","key":"1029_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/JCP.0000000000001825","volume":"44","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Bubolic S, Zhang Z, MacKenzie EM, Therrien F, Miguelez M, et al. Effects of adjunctive brexpiprazole on individual depressive symptoms and functioning in patients with major depressive disorder and anxious distress: post hoc analysis of three placebo-controlled studies. J Clin Psychopharmacol. 2024;44(2):133\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"1029_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jad.2024.06.068","volume":"361","author":"HK Kim","year":"2024","unstructured":"Kim HK, Lenze EJ, Ainsworth NJ, Blumberger DM, Brown PJ, Flint AJ, et al. Relationship between Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) total scores in older adults with major depressive disorder: an analysis of the OPTIMUM clinical trial. J Affect Disord. 2024;361:651\u20138.","journal-title":"J Affect Disord"},{"issue":"1","key":"1029_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05038-7","volume":"23","author":"F Seemuller","year":"2023","unstructured":"Seemuller F, Schennach R, Musil R, Obermeier M, Adli M, Bauer M, et al. A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients. BMC Psychiatry. 2023;23(1):548.","journal-title":"BMC Psychiatry"},{"issue":"04","key":"1029_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4236\/ojpsych.2012.24038","volume":"02","author":"S Dav\u00e9","year":"2012","unstructured":"Dav\u00e9 S, Classi P, Kim Le T, Maguire A, Ball S. Discontinuation of antidepressant therapy among patients with major depressive disorder. Open J Psychiatry. 2012;02(04):272\u201380.","journal-title":"Open J Psychiatry"},{"issue":"1","key":"1029_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12991-023-00480-z","volume":"22","author":"LM Garcia-Marin","year":"2023","unstructured":"Garcia-Marin LM, Mulcahy A, Byrne EM, Medland SE, Wray NR, Chafota F, et al. Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants. Ann Gen Psychiatry. 2023;22(1):49.","journal-title":"Ann Gen Psychiatry"},{"issue":"8","key":"1029_CR34","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41380-024-02445-4","volume":"29","author":"CH Vinkers","year":"2024","unstructured":"Vinkers CH, Kupka RW, Penninx BW, Ruhe HG, van Gaalen JM, van Haaren PCF, et al. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry. 2024;29(8):2575\u201386.","journal-title":"Mol Psychiatry"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01029-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:11:38Z","timestamp":1792581098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01029-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":34,"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01029-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stevan Geoffrey Severtson was an employee of OM1, Inc. at the time the study was conducted. Carl D. Marci is an employee of OM1, Inc. Dusica Hadzi Boskovic and Ahmad Abdrabboh are employees of Otsuka Pharmaceutical Development & Commercialization Inc. Debra F. Eisenberg is an employee of Lundbeck LLC. Ferhat Ardic is an employee of H. Lundbeck A\/S.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This secondary analysis used de-identified data and did not involve patient enrollment or access to personally identifiable information. The OM1 Real-World Data are HIPAA-compliant, and the study qualified for IRB exemption under 45 CFR 46.104(d)(4).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}